Reading between the lines of J&J's $1.75bn Alios buy
This article was originally published in Scrip
Executive Summary
Johnson & Johnson highlighted the Phase II therapy AL-8178 for respiratory syncytial virus (RSV) on 30 September when it announced the $1.75bn acquisition of Alios BioPharma, but the most valuable aspect of the deal may be the privately-held company's preclinical hepatitis C virus (HCV) programs.
You may also be interested in...
VC Roundup: Moderna Seeks Another Record-Breaking Raise; Arcus Emerges From Stealth Mode
Having raised a precedent-setting $450m venture capital round in January 2015, Moderna is well on its way to a planned $600m additional fundraising. The privately held company is keeping quiet about what it's doing with all that cash. Tioma, Nutrina and Avelas are among other firms receiving VC financing.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.